BBNX CPO Mike Mensinger reports equity grants, tax-related sale in Form 4

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Beta Bionics, Inc. Chief Product Officer Mike Mensinger reported a mix of equity grants and a small share sale. On February 27, 2026, he received a grant of 58,749 employee stock options and 109,105 shares of common stock at a price of $0.0000 per share, including a restricted stock unit award under the company’s 2025 Equity Incentive Plan. The option award will vest in 36 equal monthly installments starting March 1, 2026. On March 2, 2026, he sold 1,064 shares of common stock in an open-market transaction at a weighted average price of $12.3616 per share to cover tax withholding obligations associated with restricted stock unit vesting, leaving him with 188,793 common shares directly held after that sale.

Insider Trade Summary

Net Seller: 1,064 shares ($13,153)

Net Sell 3 txns

Insider Mensinger Mike

Role Chief Product Officer

Sold 1,064 shs ($13K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,064	$12.3616	$13K
Grant/Award	Employee Stock Option (right to buy)	58,749	$0.00	--
Grant/Award	Common Stock	109,105	$0.00	--

Holdings After Transaction: Common Stock — 188,793 shares (Direct); Employee Stock Option (right to buy) — 58,749 shares (Direct)

Footnotes (1)

Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan. The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units. The weighted average sale price for the transaction reported was $12.3616 and the range of prices were between $12.20 and $12.55. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. The shares subject to this option shall vest in 36 equal monthly installments measured from March 1, 2026.

Form 4 Insider Transactions: What Each Field Means →

03/03/2026 - 06:45 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mensinger Mike

(Last)

(First)

(Middle)

C/O BETA BIONICS, INC.

11 HUGHES

(Street)

IRVINE

92618

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Product Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/27/2026		A		109,105⁽¹⁾	A	$0	189,857	D
Common Stock	03/02/2026		S⁽²⁾		1,064	D	$12.3616⁽³⁾	188,793	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Employee Stock Option (right to buy)	$12.63	02/27/2026		A		58,749		⁽⁴⁾	02/26/2036	Common Stock	58,749	$0	58,749	D

Explanation of Responses:

1. Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan.

2. The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units.

3. The weighted average sale price for the transaction reported was $12.3616 and the range of prices were between $12.20 and $12.55. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

4. The shares subject to this option shall vest in 36 equal monthly installments measured from March 1, 2026.

	/s/ Stephen Feider, Attorney-in-Fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did BBNX Chief Product Officer Mike Mensinger report?

Mike Mensinger reported equity grants and a small share sale. He received 58,749 stock options and 109,105 common shares, then sold 1,064 shares at a weighted average price of $12.3616, primarily to satisfy tax withholding obligations tied to restricted stock unit vesting.

How many Beta Bionics (BBNX) shares did Mike Mensinger sell and at what price?

He sold 1,064 shares of Beta Bionics common stock. The weighted average sale price was $12.3616 per share, with individual transaction prices ranging between $12.20 and $12.55, according to the disclosure’s pricing footnote for this open-market tax-related sale.

What equity awards did BBNX grant to Mike Mensinger on February 27, 2026?

On February 27, 2026, Mike Mensinger received 58,749 employee stock options and 109,105 shares of common stock at $0.0000 per share. The common stock includes a restricted stock unit award granted under Beta Bionics’ 2025 Equity Incentive Plan, reflecting part of his equity compensation.

How do Mike Mensinger’s new stock options in BBNX vest over time?

The newly granted 58,749 stock options vest gradually. They are scheduled to vest in 36 equal monthly installments beginning March 1, 2026, meaning a portion becomes exercisable each month over three years, aligning his incentives with longer-term company performance.

Why did Mike Mensinger sell Beta Bionics (BBNX) shares in March 2026?

He sold 1,064 Beta Bionics shares to cover tax withholding obligations. The filing specifies that the sale proceeds were used to satisfy taxes associated with the vesting of restricted stock units, making this a tax-related transaction rather than a discretionary portfolio sale.

How many Beta Bionics (BBNX) shares does Mike Mensinger hold after these transactions?

After the March 2, 2026 sale, he directly held 188,793 shares of Beta Bionics common stock. This figure reflects his ownership following the grant and vesting-related activity, net of the 1,064 shares sold to satisfy tax withholding obligations linked to restricted stock units.